Sign In
Buy EXAS
$104.91
+0 (+0%)
At Close: Jun 03, 2026
This Chart Is Why I'm Not Worried About Guardant Health
10:20am, Thursday, 28'th Apr 2022 The Motley Fool
The leading innovator in the liquid biopsy space has huge addressable markets ahead of it.
Exact Sciences (EXAS) Q1 Earnings Top Estimates, Sales View Up
02:25pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Robust performances by the Screening and Precision Oncology segments drove Exact Sciences' (EXAS) first-quarter top line.
Exact Sciences (EXAS) Q1 Earnings Top Estimates, Sales View Up
11:33am, Wednesday, 27'th Apr 2022
Robust performances by the Screening and Precision Oncology segments drove Exact Sciences' (EXAS) first-quarter top line.
Non-COVID Sales Boost Exact Sciences' Q1 Revenue; Revises FY22 Guidance
10:03am, Wednesday, 27'th Apr 2022
Exact Sciences Corp's (NASDAQ: EXAS) Q1 revenues increased 21% Y/Y to $486.6 million, beating the average Wall Street estimate of $461.71 million. Excluding COVID-19 testing revenues, which dropped
How Exact Sciences Aims to Keep Its Lead in Cancer Tests
09:41am, Wednesday, 27'th Apr 2022
Exact Sciences raised its sales guidance for 2022 and said its Cologuard colon cancer test will prove more accurate than rival's blood-based cancer DNA screens.
Exact Sciences (EXAS) Q1 2022 Earnings Call Transcript
04:30am, Wednesday, 27'th Apr 2022 The Motley Fool
EXAS earnings call for the period ending March 31, 2022.
Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates
10:05pm, Tuesday, 26'th Apr 2022 Zacks Investment Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 7.14% and 5.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Exact Sciences Corporation (EXAS) CEO Kevin Conroy on Q1 2022 Results - Earnings Call Transcript
09:34pm, Tuesday, 26'th Apr 2022
Exact Sciences Corporation (NASDAQ:EXAS ) Q1 2022 Earnings Conference Call April 26, 2022 5:00 PM ET Company Participants Megan Jones - Senior Director of IR Kevin Conroy - Chairman and CEO Jeff Ellio
Exact Sciences (EXAS) Stock Moves -0.49%: What You Should Know
10:15pm, Friday, 22'nd Apr 2022 Zacks Investment Research
Exact Sciences (EXAS) closed at $60.68 in the latest trading session, marking a -0.49% move from the prior day.
Exact Sciences (EXAS) to Post Q1 Earnings: What's in Store?
12:48pm, Wednesday, 20'th Apr 2022 Zacks Investment Research
Robust global demand for Oncotype DX and increased Cologuard orders are likely to have driven Exact Sciences' (EXAS) Q1 performance.
Exact Sciences (EXAS) to Post Q1 Earnings: What's in Store?
10:32am, Wednesday, 20'th Apr 2022
Robust global demand for Oncotype DX and increased Cologuard orders are likely to have driven Exact Sciences' (EXAS) Q1 performance.
Exact Sciences schedules first quarter 2022 earnings call
06:00am, Friday, 08'th Apr 2022
MADISON, Wis. , April 8, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that the company plans to release its first quarter 2022 fin
2 Top Biotech Stocks to Buy for the Long Haul
02:30pm, Thursday, 07'th Apr 2022 The Motley Fool
Repligen and Exact Sciences have a proven track record with significant opportunities for continued growth.
Here's Why You Should Hold on to Exact Sciences (EXAS) Stock
12:54pm, Thursday, 31'st Mar 2022 Zacks Investment Research
Investors are optimistic about Exact Sciences (EXAS) on strong buoyed by Cologuard volume growth.
Here's Why You Should Hold on to Exact Sciences (EXAS) Stock
10:32am, Thursday, 31'st Mar 2022
Investors are optimistic about Exact Sciences (EXAS) on strong buoyed by Cologuard volume growth.
